Madrigal Pharmaceuticals, Inc.
MDGL • NASDAQ
Madrigal Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO William J. Sibold, with a market cap of $11.7B.
CEOWilliam J. Sibold
Next Earnings
Upcoming earnings announcement for Madrigal Pharmaceuticals, Inc.
Date
Thursday, April 30, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$3.93
Revenue Estimate
$301.7M
Earnings History
Past 12 earnings reports for Madrigal Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Q4 2025 | -$2.57Est: -$0.52 | -394.2% | $321.1MEst: $313.0M | +2.6% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$5.08Est: -$1.99 | -155.3% | $287.3MEst: $247.2M | +16.2% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$1.90Est: -$3.52 | +46.0% | $212.8MEst: $161.3M | +31.9% | 10-Q |
| May 1, 2025 | Q1 2025 | -$3.32Est: -$3.79 | +12.4% | $137.3MEst: $114.2M | +20.2% | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$2.71Est: -$4.12 | +34.2% | $103.3MEst: $91.3M | +13.2% | 10-K |
| Oct 31, 2024 | Q3 2024 | -$4.92Est: -$6.91 | +28.8% | $62.2MEst: $34.2M | +81.9% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$7.10Est: -$7.54 | +5.8% | $14.6MEst: $4.0M | +264.1% | 10-Q |
| May 7, 2024 | Q1 2024 | -$7.38Est: -$6.28 | -17.5% | - | — | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$5.68Est: -$5.28 | -7.6% | - | — | 10-K |
| Nov 6, 2023 | Q3 2023 | -$5.34Est: -$4.92 | -8.5% | - | — | — |
| Aug 8, 2023 | Q2 2023 | -$4.69Est: -$4.58 | -2.4% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$4.23Est: -$4.94 | +14.4% | - | — | — |